A PHASE 1/2 MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION TRIAL TO ASSESS THE SAFETY, TOLERABILITY, PHARMACODYNAMICS, AND PRELIMINARY EFFICACY OF AFTX-201 ADMINISTERED TO ADULT PARTICIPANTS WITH BCL2-ASSOCIATED ATHANOGENE 3 (BAG3) MUTATION-ASSOCIATED DILATED CARDIOMYOPATHY: UPBEAT TRIAL

Registry ID

AFTX-201-001

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

AFFINIA THERAPEUTICS

Last update

2026-03-20

Conditions

• CARDIOMYOPATHY

Related clinical trials

• A PHASE 3 GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NUCRESIRAN IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY (ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY)
• PHASE 2,ADAPTIVE,DOUBLE-BLINDED,PLACEBO-CONTROLLED,RANDOMIZED,MULTI-CENTER TRIAL TO EVALUATE THE EFFICACY,SAFETY AND TOLERABILITY OF INTRACORONARY INFUSION OF AB-1002 IN ADULT SUBJECTS WITH NYHA CLASS III HEART FAILURE AND NON-ISCHEMIC CARDIOMYOPATHY
• OPEN-LABEL EXTENSION STUDY OF LONG-TERM SAFETY AND EFFICACY OF NNC6019-0001 IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM)
• TARGETED THERAPY WITH GLYCOGEN SYNTHASE KINASE-3 INHIBITION FOR ARRHYTHMOGENIC CARDIOMYOPATHY (TARGET)

View on source registry